Meningitis| A Drug Pipeline Analysis Report| Technavio

Sept. 10, 2018 18:28 UTC

LONDON--(BUSINESS WIRE)-- Technavio has announced their latest pipeline analysis report on the drug pipeline for meningitis. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat meningitis.

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for the treatment of meningiti ...

Technavio has published a new report on the drug development pipeline for the treatment of meningitis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Meningitis: Market overview

Meningitis is the inflammation of meninges. The meninges consist of three membrane layers that cover the brain and spinal cord. It occurs when the fluid surrounding the meninges get infected. The most common cause of meninges is viral and bacterial infections. The other causes include cancer, chemical irritation, fungi, and drug allergies. Some of the viral and bacterial meningitis are contagious which can be transmitted by coughing, sneezing, or close contact.

According to a senior market research analyst at Technavio, “As per CDC the incidence of meningitis due to Neisseria meningitis is highest in the sub-Saharan African region. This hyper-endemic region extends from Senegal to Ethiopia and is characterized by seasonal epidemics during the dry season, punctuated by explosive epidemics in 8-12 years cycles. Across the meningitis belt, at least 350 million people are at risk for meningitis during these annual epidemics.”

Meningitis: Segmentation analysis

This pipeline analysis report segments the meningitis market based on therapies employed (monotherapy), RoA (intramuscular, oral, and intraventricular), therapeutic modality (small molecule, monoclonal antibody, vaccine, and recombinant enzyme), targets (peptidoglycan, ergosterol, fungal CYP51, and HER 2), MoA (immunostimulator, peptidoglycan inhibitor, ergosterol inhibitor, CYP51 inhibitor, and prophylactic vaccine), geographical segmentation (US, Finland, Peurto Rico and others) and recruitment status (active, not recruiting, completed, not yet recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, more than 62% of the molecules that are being investigated for the treatment of meningitis are vaccines.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200



Source: Technavio Research

Smart Multimedia Gallery

Technavio has published a new report on the drug development pipeline for the treatment of meningitis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

View this news release and multimedia online at:

Back to news